Lonza said it upgraded its midterm ambitions, reflecting its narrowed focus on the contract drug-manufacturing business following the planned sale of its capsules-and-health-ingredients unit. The Swiss life sciences company indicated that maturing projects in its core CDMO segment are expected to drive higher profitability over the medium term. By divesting its non-core nutrition assets, Lonza aims to streamline operations and concentrate resources on high-margin biologics manufacturing.
Management expressed confidence that the portfolio shift will improve returns and support sustained growth. The updated outlook comes as Lonza integrates recent acquisitions and optimizes capacity utilization across its global network. Analysts note the strategy aligns with industry trends toward specialization in complex molecule production.
Lonza reaffirmed its commitment to innovation and operational excellence in serving pharmaceutical clients worldwide.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing